Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,317 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Case of small-cell lung carcinoma associated with Lambert-Eaton myasthenic syndrome].
Ito T, Fukui Y, Kobayashi M, Nakayama M, Akie K, Hirokawa J, Yamamoto S, Makimura S, Yoshikawa T, Terai T, Fujiki N. Ito T, et al. Among authors: nakayama m. Nihon Naika Gakkai Zasshi. 1999 May 10;88(5):902-4. doi: 10.2169/naika.88.902. Nihon Naika Gakkai Zasshi. 1999. PMID: 10375912 Japanese. No abstract available.
Corrigendum to "Utility of Göttingen minipigs for the prediction of human pharmacokinetic profiles after intravenous drug administration" [Drug Metabol Pharmacokinet 41 (2021) 100408].
Ding N, Yamamoto S, Chisaki I, Nakayama M, Matsumoto SI, Hirabayashi H. Ding N, et al. Among authors: nakayama m. Drug Metab Pharmacokinet. 2024 Aug;57:100508. doi: 10.1016/j.dmpk.2023.100508. Epub 2023 Apr 1. Drug Metab Pharmacokinet. 2024. PMID: 38851060 No abstract available.
Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: the supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial.
Sakata Y, Shiba N, Takahashi J, Miyata S, Nochioka K, Miura M, Takada T, Saga C, Shinozaki T, Sugi M, Nakagawa M, Sekiguchi N, Komaru T, Kato A, Fukuchi M, Nozaki E, Hiramoto T, Inoue K, Goto T, Ohe M, Tamaki K, Ibayashi S, Ishide N, Maruyama Y, Tsuji I, Shimokawa H; SUPPORT Trial Investigators; SUPPORT Trial Investigators. Sakata Y, et al. Eur Heart J. 2015 Apr 14;36(15):915-23. doi: 10.1093/eurheartj/ehu504. Epub 2015 Jan 30. Eur Heart J. 2015. PMID: 25637937 Free PMC article. Clinical Trial.
Heteroduplex oligonucleotide technology boosts oligonucleotide splice switching activity of morpholino oligomers in a Duchenne muscular dystrophy mouse model.
Hasegawa J, Nagata T, Ihara K, Tanihata J, Ebihara S, Yoshida-Tanaka K, Yanagidaira M, Ohara M, Sasaki A, Nakayama M, Yamamoto S, Ishii T, Iwata-Hara R, Naito M, Miyata K, Sakaue F, Yokota T. Hasegawa J, et al. Among authors: nakayama m. Nat Commun. 2024 Sep 26;15(1):7530. doi: 10.1038/s41467-024-48204-5. Nat Commun. 2024. PMID: 39327422 Free PMC article.
3,317 results